Urogen Pharma (URGN) | Stock Overview & Key Data
Urogen Pharma Performance Comparison
Stock Range
Today's Range
Low: $18.48
High: $19.58
on August 1, 2025
52 Week Range
Low: $3.42
High: $19.74
on May 21, 2025
on July 30, 2025
All-Time High: $69.57 on May 21, 2018
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$896.3M
EPS
-3.01
P/E Ratio (TTM)
-6.55
Forward P/E
-7.29
P/B Ratio
-19.80
PEG Ratio
-7.29
Div. Yield
N/A
ROE
1,441.26%
Beta
1.028
Debt to Equity
-2.72
Financial Highlights
Profitability
Gross Margin
88.50%
Operating Margin
-182.26%
Profit Margin
-150.68%
Returns and Earnings
Return on Assets (TTM)
-29.80%
Return on Equity (TTM)
1,441.26%
EBITDA
$-106.6M
Net Income (TTM)
$-138.4M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$2.18
Quarterly Revenue Growth (YoY)
7.80%
Quarterly Earnings Growth (YoY)
7.84%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Urogen Pharma URGN | 896.31M Small-cap | 2.37% | 49.00% | 70.03% | 71.68% | 81.31% | 23.72% | 126.37% | -16.23% |
| Vertex VRTX | 118.67B Large-cap | -1.60% | 2.20% | -7.36% | -1.75% | 13.89% | -6.54% | 60.45% | 69.28% |
| Regeneron REGN | 58.89B Large-cap | -0.75% | 4.48% | -5.28% | -16.19% | -21.86% | -48.36% | -8.92% | -9.89% |
| Harmony Biosciences HRMY | 1.98B Small-cap | -8.32% | 7.40% | 15.20% | -11.75% | -1.23% | 6.17% | -34.48% | -4.44% |
| Denali Therapeutics DNLI | 1.95B Small-cap | -1.68% | -3.66% | -16.31% | -38.46% | -35.51% | -38.55% | -62.41% | -57.48% |
| Amicus Therapeutics FOLD | 1.95B Small-cap | 4.29% | 8.22% | -5.39% | -34.44% | -32.12% | -37.30% | -48.11% | -58.99% |
Ownership & Short Interest
Insider Ownership
6.89%
Institutional Ownership
106.18%
Shares Short
7M
Short Ratio
3.28
Short % of Shares Outstanding
16.03%
Average 10-Day Volume
1M
Average 90-Day Volume
2M
Urogen Pharma Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Urogen Pharma would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is URGN's 52-week high and low?
- In the last 52 weeks, Urogen Pharma reached a high of $19.74 (on July 30, 2025) and a low of $3.42 (on May 21, 2025).
- What is the market cap and P/E ratio for URGN?
- Curious about Urogen Pharma's size and valuation? Its market capitalization stands at 896.31M. When it comes to valuation, the P/E ratio (trailing twelve months) is -6.55, and the forward P/E (looking ahead) is -7.29.
- Does URGN pay dividends? If so, what's the yield?
- As for dividends, Urogen Pharma isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Urogen Pharma's main competitors or similar companies to consider before investing?
When looking at Urogen Pharma, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX118.67B Healthcare Biotechnology -6.54% 60.45% Regeneron
REGN58.89B Healthcare Biotechnology -48.36% -8.92% Harmony Biosciences
HRMY1.98B Healthcare Biotechnology 6.17% -34.48% Denali Therapeutics
DNLI1.95B Healthcare Biotechnology -38.55% -62.41% Amicus Therapeutics
FOLD1.95B Healthcare Biotechnology -37.30% -48.11% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Urogen Pharma Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Urogen Pharma's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 1,441.26%, the Debt to Equity ratio from the most recent quarter is -2.72, and its Gross Profit Margin stands at 88.50%.
- What is the recent revenue and earnings growth for URGN?
- Looking at Urogen Pharma's growth, its revenue over the trailing twelve months (TTM) was $92M. Compared to the same quarter last year (YoY), quarterly revenue grew by 7.80%, and quarterly earnings saw a YoY growth of 7.84%.
- How much of URGN stock is held by insiders and institutions?
- Wondering who owns Urogen Pharma stock? Company insiders (like executives and directors) hold about 6.89% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 106.18%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.